Cargando…

The importance of addressing multiple risk markers in type 2 diabetes: Results from the LEADER and SUSTAIN 6 trials

AIMS: To investigate to what extent multiple risk marker improvements confer lower risk of cardiovascular and kidney complications in a contemporary type 2 diabetes population. MATERIALS AND METHODS: Post‐hoc analysis of the LEADER (n = 8638; median follow‐up 3.8 years) and SUSTAIN 6 (n = 3040; medi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zobel, Emilie H., von Scholten, Bernt Johan, Hansen, Tine W., Persson, Frederik, Rasmussen, Søren, Wolthers, Benjamin, Rossing, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297860/ https://www.ncbi.nlm.nih.gov/pubmed/34676658 http://dx.doi.org/10.1111/dom.14578

Ejemplares similares

Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment
por: Zobel, Emilie H., et al.
Publicado: (2019)

Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria
por: Zobel, Emilie H., et al.
Publicado: (2017)

Effect of large weight reductions on measured and estimated kidney function
por: von Scholten, Bernt Johan, et al.
Publicado: (2017)

Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial
por: Mosenzon, Ofri, et al.
Publicado: (2020)

Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial
por: Persson, Frederik, et al.
Publicado: (2021)

The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice
por: von Scholten, Bernt Johan, et al.
Publicado: (2022)

Myocardial flow reserve assessed by cardiac (82)Rb positron emission tomography/computed tomography is associated with albumin excretion in patients with Type 1 diabetes
por: Zobel, Emilie H, et al.
Publicado: (2019)

Effect of liraglutide on expression of inflammatory genes in type 2 diabetes
por: Zobel, Emilie H., et al.
Publicado: (2021)

Effect of Liraglutide on Vascular Inflammation Evaluated by [(64)Cu]DOTATATE
por: Zobel, Emilie H., et al.
Publicado: (2021)

Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [(64)Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial
por: Jensen, Jacob K., et al.
Publicado: (2021)

The Association Between Cardiovascular Autonomic Function and Changes in Kidney and Myocardial Function in Type 2 Diabetes and Healthy Controls
por: Laursen, Jens Christian, et al.
Publicado: (2021)

Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes – An observational follow-up study
por: Frimodt-Møller, Marie, et al.
Publicado: (2018)

Non‐invasive assessment of temporal changes in myocardial microvascular function in persons with type 2 diabetes and healthy controls
por: Rasmussen, Ida K. B., et al.
Publicado: (2021)

Relation of cardiac adipose tissue to coronary calcification and myocardial microvascular function in type 1 and type 2 diabetes
por: Zobel, Emilie H., et al.
Publicado: (2020)

Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial
por: Zobel, Emilie H, et al.
Publicado: (2021)

Effect of Liraglutide on Arterial Inflammation Assessed as [(18)F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
por: Ripa, Rasmus S., et al.
Publicado: (2021)

Impaired coronary microcirculation in type 2 diabetic patients is associated with elevated circulating regulatory T cells and reduced number of IL-21R(+) T cells
por: von Scholten, Bernt Johan, et al.
Publicado: (2016)

The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes
por: Sivalingam, Suvanjaa, et al.
Publicado: (2021)

Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial
por: Wretlind, Asger, et al.
Publicado: (2022)

Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
por: Shaman, Ahmed M., et al.
Publicado: (2021)

Marker for kidney fibrosis is associated with inflammation and deterioration of kidney function in people with type 2 diabetes and microalbuminuria
por: Poulsen, Christina Gjerlev, et al.
Publicado: (2023)

Ceramides are decreased after liraglutide treatment in people with type 2 diabetes: a post hoc analysis of two randomized clinical trials
por: Wretlind, Asger, et al.
Publicado: (2023)

Urinary Alpha- and Pi-Glutathione S-Transferases in Adult Patients with Type 1 Diabetes
por: von Scholten, Bernt Johan, et al.
Publicado: (2014)

Editorial: Advanced Cardiovascular Imaging in Diabetes
por: Schick, Fritz, et al.
Publicado: (2022)

Linking Kidney and Cardiovascular Complications in Diabetes—Impact on Prognostication and Treatment: The 2019 Edwin Bierman Award Lecture
por: Rossing, Peter, et al.
Publicado: (2021)

Additive prognostic value of plasma N-terminal pro-brain natriuretic peptide and coronary artery calcification for cardiovascular events and mortality in asymptomatic patients with type 2 diabetes
por: von Scholten, Bernt Johan, et al.
Publicado: (2015)

Epicardial adipose tissue predicts incident cardiovascular disease and mortality in patients with type 2 diabetes
por: Christensen, Regitse H., et al.
Publicado: (2019)

Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE, LEADER and SUSTAIN‐6 cardiovascular outcomes trials
por: Kahkoska, Anna R., et al.
Publicado: (2020)

Epicardial adipose tissue: an emerging biomarker of cardiovascular complications in type 2 diabetes?
por: Christensen, Regitse Højgaard, et al.
Publicado: (2020)

Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes: A Randomized Crossover Trial
por: Curovic, Viktor Rotbain, et al.
Publicado: (2023)

The potential of glucagon-like peptide-1 receptor agonists in heart failure
por: Kreiner, Frederik Flindt, et al.
Publicado: (2022)

Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial
por: Mann, Johannes F. E., et al.
Publicado: (2018)

Plasma trimethylamine N-oxide and its metabolic precursors and risk of mortality, cardiovascular and renal disease in individuals with type 2-diabetes and albuminuria
por: Winther, Signe Abitz, et al.
Publicado: (2021)

Current and future therapies for type 1 diabetes
por: von Scholten, Bernt Johan, et al.
Publicado: (2021)

Insulin at 100: still central in protein-based therapy for chronic disease
por: Kurtzhals, Peter, et al.
Publicado: (2021)

Glucagon‐like peptide‐1 receptor agonists to expand the healthy lifespan: Current and future potentials
por: Kreiner, Frederik Flindt, et al.
Publicado: (2023)

Endothelial glycocalyx and cardio-renal risk factors in type 1 diabetes
por: Stougaard, Elisabeth Buur, et al.
Publicado: (2021)

YKL-40, a Marker of Inflammation and Endothelial Dysfunction, Is Elevated in Patients With Type 1 Diabetes and Increases With Levels of Albuminuria
por: Rathcke, Camilla Noelle, et al.
Publicado: (2009)

Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions
por: Eickhoff, Mie Klessen, et al.
Publicado: (2020)

Obesity-Related Kidney Disease: Current Understanding and Future Perspectives
por: Kreiner, Frederik F., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_74vt75t4sv6dr6d18n1agi6d6o